Dr. Costello on Tailoring Induction Therapy for Standard- and High-Risk Multiple Myeloma

Video

Caitlin Costello, MD, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

Caitlin Costello, MD, hematologist/medical oncologist, assistant professor of medicine, University of California, San Diego ​Health, discusses tailoring induction therapy for patients with standard-risk and high-risk multiple myeloma.

The goal of induction therapy across risk subgroups is to eliminate as much cancer as possible, Costello says. Ideally, the patient will achieve a complete remission (CR) or stringent CR. 

However, optimizing treatment for patients based on risk remains a challenge, explains Costello.

It appears that patients with high-risk multiple myeloma who have highly proliferative and aggressive disease require a more aggressive induction regimen, Costello says.

Several ongoing clinical trials are investigating how to best tailor therapy to patients with standard- vs high-risk disease, concludes Costello.


Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD